7. November 2009 00:36
Halozyme Therapeutics, Inc. today announced insulin variability study results that demonstrated reduced intrasubject absorption variability for the combination of lispro, a meal time analog insulin, plus PH20 (hyaluronidase) compared to subcutaneous injection of lispro alone.
[More]
7. November 2009 00:12
Graceway Pharmaceuticals, LLC, a portfolio company of GTCR Golder Rauner, LLC, today announced that the company has acquired from Gilead Sciences, Inc. the worldwide license, including related regulatory filings and intellectual properties, to Gilead’s investigational molecule, GS 9191, for topical use. GS 9191 is an anti-proliferative agent that works by inhibiting cellular DNA synthesis, leading to the induction of apoptosis, or programmed cell death.
[More]
6. November 2009 23:59
GeoVax Labs, Inc., an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced its third quarter 2009 financial results and provided an operational update.
[More]
6. November 2009 07:38
ZIOPHARM Oncology, Inc. presented today at the 15th Annual Connective Tissue Oncology Society (CTOS) Meeting, positive interim data from the multicenter randomized Phase II trial of palifosfamide (ZymafosTM, ZIO-201) treating patients with unresectable or metastatic soft tissue sarcoma.
[More]
c33ab7fd-4a47-496c-ab34-49adcecd0d14|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Alopecia, Anemia, Arsenic, Bone, Brain, Breast Cancer, Cancer, Capecitabine, Cell, Cyclophosphamide, Doxorubicin, Gleevec, Lymphoma, Nausea, Neuropathy, Neutropenia, New Drug Application, Oncology, Soft Tissue Sarcoma, Testicular Cancer, Xeloda
6. November 2009 03:42
Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces today that its most advanced oral antibacterial NXL103 (flopristin/linopristin), has started a Phase II clinical trial in adults with acute bacterial skin and skin structure infections (ABSSSI). The trial is designed to assess the safety and efficacy of NXL103 in comparison to oral linezolid.
[More]
5. November 2009 23:57
Helix BioPharma Corp. announced today that its Phase II trial of Topical Interferon Alpha-2b for the treatment of ano-genital warts (AGW) has completed patient enrollment, with the required 120th patient randomized to enter the trial.
[More]
5. November 2009 23:50
Amgen today announced that the Phase 3 PRIME "203" trial evaluating Vectibix® (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as a first-line treatment of metastatic colorectal cancer (mCRC) failed to meet a secondary endpoint of overall survival.
[More]
acf1eb1a-43b4-45ef-8d7d-46a881a29daf|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Antibody, Arthritis, Biotechnology, Cancer, Cell, Chemotherapy, Colorectal Cancer, Diarrhea, Irinotecan, Kidney Disease, Monoclonal Antibody, Oncology, Oxaliplatin, Rheumatoid Arthritis, Vectibix
5. November 2009 08:19
ARIAD Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009 and provided an update on corporate developments.
[More]
5. November 2009 01:33
Promedior, Inc., a leader in the development of novel therapeutics for the treatment of fibrotic diseases and tissue remodeling, announced today the publication of results from preclinical studies demonstrating that human Serum Amyloid P (hSAP) potently inhibited fibrosis in two independent model systems of kidney fibrosis.
[More]
5. November 2009 01:03
Raptor Pharmaceutical Corp., today announced that data from a clinical trial of NGX426, the Company's orally administered non-opioid, AMPA/kainate antagonist, will be presented at the 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain, to be held November 20-21, 2009 in San Francisco.
[More]
5. November 2009 01:01
Inspire Pharmaceuticals, Inc. announced today patient enrollment is complete in three of its late-stage clinical trials.
[More]
4. November 2009 23:47
Dong-A PharmTech Co. Ltd., announced that its U.S. partner, Warner Chilcott plc, has initiated two, phase III trials for udenafil, a new long acting drug under development for erectile dysfunction (ED). Each randomized, double-blind, placebo-controlled trial is designed to evaluate the safety and efficacy of udenafil, an orally administered selective inhibitor of phosphodiesterase versus placebo.
[More]
4. November 2009 23:28
BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, has presented results on miconazole Lauriad® at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Philadelphia (October 29 – November 1st).
[More]
4. November 2009 08:40
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, today announced the initiation of a Phase 1 clinical study of ACE-041, a novel angiogenesis inhibitor that binds to and prevents members of the TGF-β superfamily from signaling through the activin receptor-like kinase 1 (ALK1) receptor.
[More]
4. November 2009 08:15
Data were presented from the phase IIa trial (OPERA-1) for TMC435 at the ongoing 60th annual meeting of the American Association for the Study of Liver Diseases in Boston, USA.
[More] 
Subscribe